Axis Therapeutics Information

View Top Employees from Axis Therapeutics

Axis Therapeutics, a joint venture between Athenex, Inc. (NASDAQ: ATNX) and XLifeSc, is a cancer immunotherapy company focused on the development of T cell therapies. The company is developing a novel class of innovative TCR-T therapies designed to harness the immune system to recognize and destroy cancerous cells and aims to develop more effective cell therapies for cancer patients around the world. Through the TCR-T technology platform, the Company has generated engineered T cells with higher binding affinity and specificity for a defined tumor antigen. In 2018, Axis Therapeutics licensed from XLifeSc, the global rights to the TAEST technology, excluding China (XLifeSc retains the mainland China rights). In this territory, Axis Therapeutics is leading the research, development and commercialization efforts of T cell receptor-engineered T cells (TCR-T, including the TAEST technology), a form of cancer immunotherapy.

Website	http://www.axistherapeutics.com
Revenue	$4 million
Employees	1 (1 on RocketReach)
Address	1001 Main St Ste 600, Buffalo, New York 14203, US
Phone	+1 705-879-3265
Industry	Hospitals & Clinics, Healthcare
Competitors	Roche, Novartis, Merck & Co., Inc., Pfizer, Sanofi, AstraZeneca, Bristol Myers Squibb, Amgen, Gilead Sciences, Lilly India +41 more (view full list)
SIC	SIC Code 80 Companies, SIC Code 804 Companies
NAICS	NAICS Code 621 Companies, NAICS Code 6213 Companies, NAICS Code 621399 Companies, NAICS Code 62 Companies, NAICS Code 62139 Companies